Philip L. Lorenzi

TL;DR: Although the gene expression data are largely concordant between them, the reported drug-sensitivity measures and subsequently their association with genomic features are highly discordant and the authors call for standardization of drug-response measurements, to aid the discovery of robust biomarkers and mechanisms of drug response and hence progress in personalized cancer medicine.

TL;DR: NIA technology provides an ability to characterize coordinate phosphorylation of individual AKT molecules providing important information about AKT isoform-specific phosphorylated, which is required for optimal development and implementation of drugs targeting aberrant AKT activation.

TL;DR: It is demonstrated that EWS‐FLI1 reprograms the metabolism of EWS cells and that serine‐glycine metabolism or glutamine uptake are potential targetable vulnerabilities in this tumor type.

TL;DR: This study provides new insight into L-ASP’s mechanism of action, and the optimized analytical method can be extended, with only slight modification, to other metabolically active amino acids, related compounds, and a range of cultured cell types.

TL;DR: In this paper, the authors showed that co-targeting MCL-1 and BCL-2 improves the efficacy of venetoclax/decitabine-resistant acute myeloid leukemia.